Pulse Biosciences Q2 net loss $24.7M; NANOPULSE-AF enrollment ahead of schedule

PULSE BIOSCIENCES, INC.

Q2 revenue $0.4M; GAAP net loss ($24.7M) vs ($19.2M) year ago; non-GAAP net loss ($19.4M).
Cash $101.6M at June 30, 2026; raised $46.8M net via ATM in Q2, plus $10.7M post-quarter.
NANOPULSE-AF pivotal study surpassed 82 evaluable patients; enrollment target raised to 164, completion expected early Q4.
New $75M ATM facility in place; shelf registration for additional $125M provides financing flexibility.
Soft tissue revenue $434k, sequential growth; PRECISE-BTN study to complete enrollment within month.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.